Seattle-based Variant Bio has expanded its multi-year research collaboration and license agreement with Boehringer Ingelheim into cardiovascular disease, with potential payments exceeding USD 250 million.
Under the expanded agreement, Variant Bio will apply its Inference platform — which combines large language models, machine learning, and statistical genetics — to discover and validate novel targets for cardiovascular disease. Variant Bio said the platform interrogates hundreds of billions of data points drawn from proprietary genomic, deep-phenotyping, and multi-omic data from studies involving diverse populations worldwide. Under the division of responsibilities, Variant Bio handles target discovery and validation using its platform and data assets, while Boehringer Ingelheim contributes scientific expertise in cardiovascular and renal-metabolic diseases.
Variant Bio is eligible for an upfront payment, platform access payments, and milestone payments totaling potentially more than USD 250 million under the cardiovascular expansion. The deal structure explicitly names "platform access payments" as a distinct payment category alongside upfront and milestone payments, reflecting ongoing use of the Inference platform rather than a one-time license grant. Royalty terms were not disclosed.
The expansion builds on the original kidney disease collaboration announced in January 2026, which carried potential payments exceeding USD 120 million and similarly applied the Inference platform to novel target identification.